Drug Approval | April 28, 2025
Biocon Biologics receives positive CHMP opinions for biosimilar Denosumab in Europe
The positive opinions are based on applications submitted by Biosimilar Collaborations Ireland Limited
The positive opinions are based on applications submitted by Biosimilar Collaborations Ireland Limited
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
The closing of the Block Acquisition is now expected to be completed by Q3 2025
Bayer expects 2025 to be the most difficult year of its turnaround
Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA modelsfeatured in two peer-reviewed articles
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
Akums and TNAU will collaborate to strengthen research through shared expertise and innovative agricultural solutions, to foster innovation in formulation development
The 27 greenfield labs across the country ensure timely and accurate reporting
This unit will focus on the manufacturing of health and wellness equipment
The newly inaugurated facility bridges this gap by offering metro-grade treatment closer to home
Subscribe To Our Newsletter & Stay Updated
